PDF(Pubmed)
Abstract：
Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient\'s complete remission has persisted for 20 months after HSCT.
摘要：
针对T细胞急性淋巴细胞白血病/淋巴瘤（T-ALL/LBL）的靶向CD7的嵌合抗原受体T细胞（CART）在一些临床试验中显示出有希望的疗效和安全性。然而,其中大多数与异基因造血干细胞移植（allo-HSCT）桥接。我们描述了在allo-HSCT后难治性T淋巴母细胞淋巴瘤的情况下，预防性供体来源的抗CD7CAR-T治疗的成功治疗。由于T淋巴细胞的低质量，他们无法接受自体抗CD7CAR-T产品。迄今为止,患者在HSCT后完全缓解持续20个月。
